FibroGen Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
FGEN Nasdaq 8731 https://www.fibrogen.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for FibroGen Inc

Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More - Aug 31st, 2023 2:15 pm
FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% - Aug 30th, 2023 3:09 pm
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy - Aug 29th, 2023 8:15 pm
Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround - Aug 16th, 2023 1:35 pm
Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation? - Aug 9th, 2023 1:14 pm
Q2 2023 FibroGen Inc Earnings Call - Aug 8th, 2023 2:08 pm
FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Aug 7th, 2023 11:30 pm
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates - Aug 7th, 2023 9:40 pm
FibroGen Reports Second Quarter 2023 Financial Results - Aug 7th, 2023 8:01 pm
FibroGen Announces Leadership Transition - Jul 25th, 2023 11:00 am
FibroGen to Report Second Quarter 2023 Financial Results - Jul 24th, 2023 11:00 am
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% - Jul 21st, 2023 11:17 am
FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Jul 14th, 2023 1:55 pm
Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround - Jul 11th, 2023 1:35 pm
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? - Jul 1st, 2023 12:46 pm
FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study - Jun 27th, 2023 4:45 pm
FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug - Jun 26th, 2023 8:04 pm
FibroGen, Inc.'s (NASDAQ:FGEN) institutional investors lost 4.0% last week but have benefitted from longer-term gains - Jun 26th, 2023 3:34 pm
UPDATE 2-FibroGen's drug fails late-stage trial for treating lung disease - Jun 26th, 2023 11:22 am
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis - Jun 26th, 2023 11:04 am